Clinical Trials
40 trialsDP-04
AstraZeneca
STARTRK-2
Hoffmann-La Roche
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
iOmx Therapeutics AG
TraveraRTGx
Travera Inc
GPX
Fluidx Medical Technology, Inc.
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Kazia Therapeutics Limited
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
PRESERVE-001
OncoC4, Inc.
ROOT
Taproot Health
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
DUET-3
Xencor, Inc.
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
ALpha-T
Hoffmann-La Roche
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
A Bioequivalence Study of Sunitinib Malate Capsules.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
REVEAL
Nektar Therapeutics
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
PIONEER
SpeciCare
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
Mirror Biologics, Inc.
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Merck Sharp & Dohme LLC
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 2 Study in Patients With MiT Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)